HB 1138 would require certain Indiana state employee health plans to cover two obesity-related treatments for eligible members: anti-obesity medication and intensive behavioral and lifestyle therapy. The bill defines anti-obesity medication as FDA-approved medication prescribed by a physician to help an individual achieve and maintain a healthy weight, and it defines intensive behavioral and lifestyle therapy as counseling or treatment focused on nutrition, exercise support, and other behavior changes to manage obesity.
The coverage mandate would apply to state employee health plans established, amended, or renewed after June 30, 2025, with an effective date of July 1, 2025. The bill is limited to individuals covered under a state employee health plan who have been diagnosed with obesity, and it uses existing Indiana insurance and medical licensing definitions to identify the plans and providers covered by the requirement.
Impact
The bill would add a new section to Indiana Code 5-10-8, creating a statutory coverage requirement for state employee health plans. In practical terms, it would require the state’s self-insured employee health program and prepaid health care delivery contracts to include benefits for obesity medications and intensive behavioral therapy for qualifying enrollees, potentially affecting plan design, claims administration, and state health benefit costs. It does not appear to regulate private insurance generally; its effect is limited to state employee coverage.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears neutral-to-supportive in purpose, with the bill framed as a health coverage expansion for a recognized medical condition. The caption and structure suggest a straightforward benefits mandate rather than a controversial restructuring of the insurance code, but there is no available discussion record to show whether lawmakers or stakeholders expressed support or opposition.
Contention
No committee transcript or vote history was provided, so there are no documented points of contention in the record supplied here. Potential areas of debate, if raised, would likely involve the cost of requiring coverage, whether obesity medications should be treated like other covered chronic-condition treatments, and whether the mandate should apply only to state employee plans rather than the broader insurance market. The bill’s limitation to diagnosed obesity and physician-prescribed FDA-approved medication may also be relevant to any discussion about medical necessity and utilization controls.